FDA Oncology Announcements

Anti-CTLA-4 × Dermatologic × Clear all

2 Announcements

Nivolumab in combination with ipilimumab

Drugs: Opdivo (nivolumab) · Anti-PD-1 antibody, ipilimumab · Anti-CTLA-4 antibody
Condition: Dermatologic

Ipilimumab

Drug: YERVOY (ipilimumab) · Anti-CTLA-4 antibody
Condition: Dermatologic